Lorbrena (lorlatinib)

News alerts, weekly reports and conference planners

Company:

CStone Pharma, Pfizer

Drug class:

ALK inhibitor, ROS1 inhibitor

Related drugs:

‹

›

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK translocation	Soft Tissue Sarcoma	ALK translocation	Soft Tissue Sarcoma	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
EML4-ALK variant 1	Non Small Cell Lung Cancer	EML4-ALK variant 1	Non Small Cell Lung Cancer	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B
EML4-ALK variant 3	Non Small Cell Lung Cancer	EML4-ALK variant 3	Non Small Cell Lung Cancer	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ALK positive	Neuroblastoma	ALK positive	Neuroblastoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ALK positive	Lung Cancer	ALK positive	Lung Cancer	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ROS1 positive	Lung Cancer	ROS1 positive	Lung Cancer	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	crizotinib + lorlatinib Sensitive: C2 – Inclusion Criteria crizotinib + lorlatinib Sensitive : C2	crizotinib + lorlatinib Sensitive: C2 – Inclusion Criteria crizotinib + lorlatinib Sensitive : C2
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ALK positive + ALK mutation	Non Small Cell Lung Cancer	ALK positive + ALK mutation	Non Small Cell Lung Cancer	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3
ALK positive + ALK G1202R	Non Small Cell Lung Cancer	ALK positive + ALK G1202R	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
ALK positive + ROS1 positive	Lung Cancer	ALK positive + ROS1 positive	Lung Cancer	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
ALK F1174L + ALK G1202R	Non Small Cell Lung Cancer	ALK F1174L + ALK G1202R	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3
MAP2K1 mutation	Non Small Cell Lung Cancer	MAP2K1 mutation	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
KRAS amplification	Non Small Cell Lung Cancer	KRAS amplification	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
TP53 mutation + ALK positive	Non Small Cell Lung Cancer	TP53 mutation + ALK positive	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3
ROS1 positive + TP53 positive	Non Small Cell Lung Cancer	ROS1 positive + TP53 positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3	lorlatinib Sensitive: C3 – Early Trials lorlatinib Sensitive : C3
ALK rearrangement + MET amplification	Non Small Cell Lung Cancer	ALK rearrangement + MET amplification	Non Small Cell Lung Cancer	crizotinib + lorlatinib Sensitive: C3 – Early Trials crizotinib + lorlatinib Sensitive : C3	crizotinib + lorlatinib Sensitive: C3 – Early Trials crizotinib + lorlatinib Sensitive : C3

Lorbrena (lorlatinib)

Associations
(94)

Associations
(94)

Lorbrena (lorlatinib)

Associations(94)

Associations(94)

Associations
(94)

Associations
(94)